Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS malignancy consortium protocol 042

Journal of Clinical Oncology

Volumn 32, Issue 5, 2014, Pages 402-408

  Koon, Henry B ^a   Krown, Susan E ^c   Lee, Jeannette Y ^d   Honda, Kord ^b   Rapisuwon, Suthee ^e   Wang, Zhenghe ^a   Aboulafia, David ^f   Reid, Erin G ^g   Rudek, Michelle A ^h   Dezube, Bruce J ⁱ   Noy, Ariela ^c  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^e GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^f VIRGINIA MASON MEDICAL CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; EFAVIRENZ; IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RITONAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; AIDS ASSOCIATED KAPOSI SARCOMA; AIDS RELATED COMPLEX; ANTIVIRAL THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CELLULITIS; CHRONOTHERAPY; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DEHYDRATION; DEPRESSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; HYPOPHOSPHATEMIA; KAPOSI SARCOMA; MALE; MOOD DISORDER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUTATION RATE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GROWTH; BLOOD; DISEASE COURSE; DRUG ANTAGONISM; ENZYMOLOGY; GENETICS; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MUTATION; PATHOLOGY; PILOT STUDY; TIME; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTINEOPLASTIC AGENTS; BENZAMIDES; CYTOKINES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; PILOT PROJECTS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SARCOMA, KAPOSI; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84897574876     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.48.6365     Document Type: Article

References (22)

1. Schalling M, Ekman M, Kaaya EE, et al: A role for a new herpes virus (KSHV) in different forms of Kaposi's sarcoma. Nat Med 1:707-708, 1995
2. Ensoli B, Nakamura S, Salahuddin SZ, et al: AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. Science 243:223-226, 1989 (Pubitemid 19035359)
3. Masood R, Cai J, Zheng T, et al: Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDSKaposi sarcoma. Proc Natl Acad Sci U S A 94:979-984, 1997 (Pubitemid 27074433)
4. Miles SA, Rezai AR, Salazar-González JF, et al: AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. Proc Natl Acad Sci U S A 87:4068-4072, 1990
5. Miles SA: Pathogenesis of human immunodeficiency virus-related Kaposi's sarcoma. Curr Opin Oncol 4:875-882, 1992
6. Stürzl M, Roth WK, Brockmeyer NH, et al: Expression of platelet-derived growth factor and its receptor in AIDS-related Kaposi sarcoma in vivo suggests paracrine and autocrine mechanisms of tumor maintenance. Proc Natl Acad Sci U S A 89:7046-7050, 1992
7. Cornali E, Zietz C, Benelli R, et al: Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi's sarcoma. Am J Pathol 149:1851-1869, 1996 (Pubitemid 26415207)
8. Moses AV, Jarvis MA, Raggo C, et al: Kaposi's sarcoma-associated herpesvirus-induced upregulation of the c-kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cells. J Virol 76:8383-8399, 2002 (Pubitemid 34809091)
9. Talpaz M, Silver RT, Druker BJ, et al: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood 99:1928-1937, 2002 (Pubitemid 34525471)
10. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002 (Pubitemid 34879334)
11. Rubin BP, Schuetze SM, Eary JF, et al: Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 20:3586-3591, 2002 (Pubitemid 34983217)
12. Koon HB, Bubley GJ, Pantanowitz L, et al: Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J Clin Oncol 23:982-989, 2005 (Pubitemid 46202318)
13. Berman E, Nicolaides M, Maki RG, et al: Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 354:2006-2013, 2006
14. Parise RA, Ramanathan RK, Hayes MJ, et al: Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma. J Chromatogr B Analyt Technol Biomed Life Sci 791:39-44, 2003 (Pubitemid 36638736)
15. Sparano BA, Egorin MJ, Parise RA, et al: Effect of antacid on imatinib absorption. Cancer Chemother Pharmacol 63:525-528, 2009
16. Chowdhury F, Williams A, Johnson P: Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling. J Immunol Methods 340:55-64, 2009
17. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
18. Noy A, Scadden DT, Lee J, et al: Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: From the AIDS Malignancy Consortium and IM862 Study Team. J Clin Oncol 23:990-998, 2005 (Pubitemid 46205948)
19. Cianfrocca M, Cooley TP, Lee JY, et al: Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: A phase I AIDS Malignancy Consortium study. J Clin Oncol 20:153-159, 2002 (Pubitemid 34032606)
20. Larson RA, Druker BJ, Guilhot F, et al: Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: A subanalysis of the IRIS study. Blood 111:4022-4028, 2008
21. Baker AF, Dragovich T, Ihle NT, et al: Stability of phosphoprotein as a biological marker of tumor signaling. Clin Cancer Res 11:4338-4340, 2005 (Pubitemid 40825621)
22. Espina V, Edmiston KH, Heiby M, et al: A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics 7:1998-2018, 2008